I'll research IFF thoroughly before writing the preview. Let me start by gathering recent filings, earnings, and news.Let me read the most recent quarter's earnings materials and check recent news/filings.Let me gather recent news, press releases, and stock price data leading into the report.Let me check the term loan 8-K and search for news on the Food Ingredients sale process.The Food Ingredients sale to CVC is the key development. Let me read the details and look for the official announcement.Let me pull the year-ago Q2 2025 figures for comparison and check for analyst consensus.Let me quickly attempt to pull sell-side/consensus context and any recent daily news.I have what I need. Here's the earnings preview.
Reports: After market close, Tuesday, August 4, 2026 · Call the following morning · NYSE: IFF Stock: ~$80.60 (Aug 3 close), up ~18% YTD from ~$68 to start the year, trading near its recent highs
This is a "look-through" quarter. Management has already told investors Q2 will be the soft point of the year, so the print itself matters less than three things: (1) whether the guided Q2 EBITDA step-down is as-advertised or worse, (2) whether full-year guidance holds, and (3) any fresh detail on the $4.3B Food Ingredients sale to CVC — the transformative event that reshapes IFF into a three-segment company.
On the Q1 call (May 6), CFO Michael DeVeau guided Q2 adjusted operating EBITDA below Q1's $568M, citing three drivers: 1. Moderating growth vs. a strong Q1 (Q1 delivered +3% comparable currency-neutral sales and +8% CN EBITDA). 2. Unfavorable price-to-cost: energy and logistics inflation (tied to higher Brent) rising in double digits, while pricing surcharges are only phased in over the quarter — a timing gap that squeezes margin before it recovers. 3. Middle East / Fine Fragrance softness: IFF's largest Middle East exposure sits in Scent's Fine Fragrance business; slower demand plus temporary supply-chain/packaging disruptions create a negative volume and mix hit.
Management expects all three pressures to ease through H2 as surcharges take full effect. So a sequential EBITDA decline is expected and priced in — watch the magnitude and the commentary on H2 recovery, not the direction.
Announced June 1, 2026 (after WSJ/Reuters reports on May 29): - Buyer: an affiliate of CVC Capital Partners - Enterprise value: ~$4.3B (~10x EV/EBITDA); ~$3.8B net cash proceeds to IFF - Timing: expected to close by end of Q2 2027 - EPS impact: expected dilutive in the first 12 months - Balance sheet mechanics: IFF put a $1.0B delayed-draw term loan in place (June 23) to refinance €800M of 1.8% notes due Sept 2026; the term loan must be prepaid with 100% of FI sale proceeds.
Why it matters: This completes CEO Erik Fyrwald's two-year portfolio-simplification arc (after Pharma Solutions to Roquette for $2.85B and the smaller Bunge soy-crush sale). Post-close, IFF becomes a focused three-segment business: Taste, Health & Biosciences, and Scent. Note the irony that FI has actually been executing well (Q1: $839M sales, $114M EBITDA, 13.6% margin; management targets >14% for 2026) — its strong run improved the sale price.
What to listen for on the call: - Use of the ~$3.8B: management has signaled it will keep net leverage around 2.5x and use excess to offset dilution via buybacks, plus fund bolt-ons/organic reinvestment. - Updated pro-forma segment structure, margins, and any new medium-term financial framework for the slimmed-down company. - Regulatory/closing confidence and any pre-close cash costs.
Reaffirmed at Q1: - Sales: $10.5–10.8B (1–4% comparable CN growth); FX ~+1% tailwind; divestitures ~-5% headwind - Adjusted operating EBITDA: $2.05–2.15B (3–8% CN growth) with margin expansion
Management characterized the year as "a different shape" — stronger Q1, softer Q2, recovery in H2 — but with an unchanged full-year goal. Given the Q1 beat, the debate is whether they nudge guidance up, hold, or trim on Middle East uncertainty. A simple reaffirmation is most likely; any raise would be a positive surprise, any cut a red flag.
| Segment | Q1'26 EBITDA / margin | Story into Q2 |
|---|---|---|
| Taste | $153M / 23.3% (+18% CN) | Best performer; Q1 margin was a high-water mark. Management flagged this level of leverage won't repeat — expect normalization. |
| Health & Biosciences | $153M / 25.7% (+7% CN) | Enzymes/cultures strong; North America "Health" sub-business is the turnaround — expected to inflect from flat in H1 to growth in H2, accelerating into 2027. |
| Scent | $148M / 22.7% (−2% CN) | The pressure point: Fine Fragrance/Middle East softness in Q2, plus a persistent drag from commodity Fragrance Ingredients (~half of ~$500M FI ingredient sales) facing Indian/Chinese price competition — being deemphasized through 2027. |
| Food Ingredients | $114M / 13.6% (+12% CN) | Now the "held-for-sale" crown jewel; watch for margin durability and any reclassification/discontinued-ops treatment. |
Expect a deliberately weak-looking Q2 — sequentially lower EBITDA, roughly flat/down EPS (~$1.13–1.14) — that management has pre-committed to. The stock, up ~18% YTD and near highs after a +17% pop on the Q1 beat, is pricing in execution and the CVC deal, so the risk/reward hinges on: - Positive: full-year guide held/raised, Q2 downdraft no worse than guided, concrete plan for the $3.8B in proceeds (buybacks + deleveraging), and evidence the H2 recovery/Health turnaround is on track. - Negative: a deeper-than-expected Middle East/Fine Fragrance hit, guidance cut, weaker FCF, or any wobble on the CVC deal timeline or terms.
Given how carefully management pre-framed this quarter, the narrative on the second half and the newly-focused three-segment IFF will drive the stock more than the Q2 numbers themselves.
Sources: IFF Q1 2026 earnings call & release (May 5–6, 2026); Q2 2025 earnings release (Aug 5, 2025); IFF 8-K term-loan filing (June 23, 2026); IFF/CVC Food Ingredients sale announcement (June 1, 2026) and related news (May 29, 2026); consensus and preview estimates from Zacks/TradingView/MarketBeat/Defense World (late July–Aug 2026); Finnhub price data.
This is a research summary, not investment advice.